You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Medtronic
Express Scripts
McKinsey
AstraZeneca

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,770,570

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,770,570 protect, and when does it expire?

Patent 9,770,570 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in twelve countries.

Summary for Patent: 9,770,570
Title:Apparatus and method for monitoring nitric oxide delivery
Abstract: Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises an indicator to inform a user of the apparatus when the flow of breathing gas rises above or falls below a predetermined level or range. Also described is a method of monitoring nitric oxide delivery, wherein the flow of breathing gas is measured and displayed. In some embodiments, an alert is provided when the flow of breathing gas rises above or falls below a predetermined level or range.
Inventor(s): Schnitman; Robert (Colchester, CT), Medicis; Joseph J. (Syracuse, NY), Potenziano; Jim (Binghamton, NY), Acker; Jaron (Madison, WI), Schmidt; Jeffrey (Oregon, WI)
Assignee: Mallinckrodt Hospital Products IP Limited (Dublin, IE)
Application Number:13/671,057
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 9,770,570

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,770,570

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012335937   Start Trial
Australia 2014244334   Start Trial
Australia 2018204804   Start Trial
Australia 2020202541   Start Trial
Canada 2854776   Start Trial
Canada 2905644   Start Trial
Denmark 2968824   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Harvard Business School
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.